1. enquiry@psmarketresearch.com www.psmarketresearch.com Interleukin-6 (IL-6) Inhibitors Therapeutics Pipeline to Witness Many Collaborations in Coming Years

2. The study analyzed that the IL-6 inhibitors therapeutics pipeline comprises approximately 18 active drug candidates in different stages of development. Interleukin-6 inhibitors acts on the IL-6 receptor. IL-6 receptors belong to a group of cytokine receptors that are expressed by leukocytes and plays an important role in the functioning of the immune system. It has a characteristic role in systemic inflammation in numerous disease conditions, including rheumatoid arthritis, and psoriatic arthritis. IL-6 inhibitors therapeutics pipeline in 2017 Interleukin-6 (IL-6) Inhibitors Therapeutics

3. According to the research findings, most of the drug candidates of the IL-16 inhibitors are being developed as the monoclonal antibody. Access Report Summary with Detailed TOC on "Interleukin-6 (IL-6) Inhibitors Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” at: https://www.psmarketresearch.com/market- analysis/interleukin-6-inhibitors-therapeutics-pipelinehttps://www.psmarketresearch.com/market- analysis/interleukin-6-inhibitors-therapeutics-pipeline Insights on pipeline segments Interleukin-6 (IL-6) Inhibitors Therapeutics

4. The positive clinical results from IL-6 inhibitors drug candidates have been driving the pipeline growth. GlaxoSmithKline plc presented results from two pivotal Phase III studies (NCT01606761; NCT02019472) evaluating subcutaneous sirukumab. In both the studies, sirukumab met the primary endpoint showing significant improvement in the signs and symptoms of moderately to severely active rheumatoid arthritis compared to placebo. Positive Clinical Results of IL-6 Inhibitors Therapeutics Candidates Interleukin-6 (IL-6) Inhibitors Therapeutics

5. In January 2017, Tiziana Life Sciences plc acquired an exclusive world-wide license for NI-1201, a fully human anti-IL-6R monoclonal antibody (mAb), from Novimmune SA. In exchange for the exclusive license from Novimmune SA, Tiziana Life Sciences plc agreed to an upfront cash payment, milestone payments, and a royalty on future sales. Some of the key players developing drugs for the treatment of IL-6 inhibitors therapeutics include GlaxoSmithKline plc, Chugai Pharmaceutical Co., Ltd., Vitaeris Inc. and others. Various collaborations for IL-6 Inhibitors therapeutics drug development Interleukin-6 (IL-6) Inhibitors Therapeutics

6. https://www.psmarketresearch.com/market- analysis/interleukin-6-inhibitors-therapeutics-pipeline/report- sample Download report sample at: Interleukin-6 (IL-6) Inhibitors Therapeutics

7. enquiry@psmarketresearch.com www.psmarketresearch.com For information regarding permissions and other queries Kindly write to: US/Canada Toll-Free: 1-888-778-7886 GET IN TOUCH THANK YOU!